TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03958331

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Automated Digital Reminders
Description: Reminders from electronic monitors via texts or alarms/lights

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Digital Reminders
Description: Reminders from electronic monitors via texts or alarms/lights

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individualized Adherence Feedback Report
Description: Feedback report on individual adherence behaviors
Study: NCT04067960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03958331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Adherence Feedback Report with Social Norms
Description: Feedback report on individual adherence behaviors compared to other adolescents with epilepsy
Study: NCT03132467

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study: NCT00542178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypoglycemic Agents
Description: Multiple drugs including insulins and oral hypoglycemia agents for HbA1c less than 6%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard glycemia control
Description: A strategy of glycemia drugs for HbA1c 7% - 7.9%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive BP treatment
Description: A strategy of multiple BP agents to reduce SBP less than 120 mm Hg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard BP control
Description: A strategy of BP drugs for SBP less than 140 mm Hg
Study: NCT00092833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: ezetimibe
Description: Ezetimibe (MK0653) 10 mg once daily for 3 years.
Study: NCT03574844

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saccharomyces cerevisiae, dose 500
Description: Experimental arm

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saccharomyces cerevisiae, dose 1000
Description: Experimental arm

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator arm
Study: NCT02794350

Intervention type: DEVICE
Intervention: Cochlear implant
Study: NCT05641311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: Tablet for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: Tablet for oral use.
Study: NCT02732678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PROPRANOLOL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PROPRANOLOL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PROPRANOLOL
Study: NCT04266080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit Inspire HR
Description: assessing step counts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionaires
Description: Patient-Reported Outcomes Measurement Information System (PROMIS)
Study: NCT01315886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL fentanyl
Description: SL fentanyl will be administered during 7- 15 BTcP episodes during a maximum period of 21 days, following a baseline period with standard BTcP treatment. The start dose of SL fentanyl is selected individually according to a standardized conversion ratio. The maximum start dose is limited to 400 μg. For a single BTcP episode no more than two (2) tablets or a maximum dose of 800 μg should be given.
Study: NCT00005786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03432780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hormone and radiation therapy

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hormone and radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Study: NCT04473586

Intervention type: DEVICE
Group type: OTHER
Intervention: Spartan Cube CYP2C19 System
Description: Using buccal material, determine the genotype of the \*2, \*3 and \*17 SNPs of the CYP2C19 gene on the Spartan Cube CYP2C19 System.

Intervention type: DEVICE
Group type: OTHER
Intervention: Spartan Cube CYP2C19 System
Description: Using buccal material, determine the genotype of the \*2, \*3 and \*17 SNPs of the CYP2C19 gene on the Spartan Cube CYP2C19 System.
Study: NCT02812459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Kinesio taping is a new taping modality which act diminishing pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Stimulation
Description: Electrical stimulation therapy is a electrical current that allow patients diminish pain.
Study: NCT01174199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography/computed tomography
Description: PET scan
Study: NCT03671525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimodipine
Description: Subject will receive two 30mg capsules of nimodipine during study visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Two coconut oil capsules that mimic the size and color of the nimodipine capsules
Study: NCT03993392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TM buprenorphine
Description: 4mg TM buprenorphine, investigator choice as to brand

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUBLOCADE
Description: 300mg subcutaneous injection
Study: NCT04126330

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic, Omega-3, Vitamin D supplement
Description: The first supplement we would like to assess is named VNP and is composed by Omega-3 Active and vitamin D. It contains a total of 1100 mg fish oils: 640 mg Omega-3 and with 300 mg eicosapentaenoic acid (EPA), 220 mg docosahexaenoic acid (DHA) plus 200 IU Vitamin D per daily dose (2 capsules).~The second supplement we investigate is four-strain probiotics combination based on the commercially available formulation HOWARU® by DuPont; two capsules containing 10 billion CFU total (supplied by Pfizer but manufactured by Danisco, DuPont). The probiotic specific composition, contains equal amounts of each strain per capsule (1.25 x 109 CFU each): Bifidobacterium lactis Bi-07, Lactobacillus paracasei Lpc-37, Lactobacillus acidophilus NCFM, Bifidobacterium lactis Bl-04. One capsule contains 5 billion CFU (Swedish milliards).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic, Omega-3, Vitamin D supplement
Description: The first supplement we would like to assess is named VNP and is composed by Omega-3 Active and vitamin D. It contains a total of 1100 mg fish oils: 640 mg Omega-3 and with 300 mg eicosapentaenoic acid (EPA), 220 mg docosahexaenoic acid (DHA) plus 200 IU Vitamin D per daily dose (2 capsules).~The second supplement we investigate is four-strain probiotics combination based on the commercially available formulation HOWARU® by DuPont; two capsules containing 10 billion CFU total (supplied by Pfizer but manufactured by Danisco, DuPont). The probiotic specific composition, contains equal amounts of each strain per capsule (1.25 x 109 CFU each): Bifidobacterium lactis Bi-07, Lactobacillus paracasei Lpc-37, Lactobacillus acidophilus NCFM, Bifidobacterium lactis Bl-04. One capsule contains 5 billion CFU (Swedish milliards).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo generated for probiotic and omega-3/vitamin D supplements
Study: NCT00542178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Blinded fenofibrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 20-40 mg/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 20-40 mg/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03836404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iliac crest reconstruction surgery
Description: When autologous bone graft is needed for the treatment of non-unions or bone defects, is harvested from the pelvic iliac crest. Harvested tricortical graft blocks are used to facilitate fusion of joints (ie pubis symphysis, sacroiliac joint), to structurally support metaphyseal areas of articular impaction injuries and to fill in metaphyseal bone voids. The GreenBone device, with its inherent physical and biomimic properties, possesses similar structural properties to bone, thus, being the ideal material to be used for the treatment of the bone defect (3- 4cm) induced from the harvested tricortical iliac crest, restoring therefore the pelvic anatomy and minimising the risk of chronic pain, haematoma formation and herniation of the abdominal contents.
Study: NCT00640003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Drug given by orally via capsules. Escalation steps in 4-day intervals. Step 1: 5mg QAM. Step 2: 5mg BID. Step 3: 5mg TID. Step 4: 10mg QAM, 5mg BID. Step 5: 10mg BID, 5mg QMid-day. Step 6: 10mg TID. Step 6 will last up to 2 weeks. De-escalation will start from highest dose step and work backwards in 2-day intervals. Complete drug administration of escalating, staying constant at 10mg TID and de-escalating will be done with both drug and placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Drug given by orally via capsules. Escalation steps in 4-day intervals. Step 1: 5mg QAM. Step 2: 5mg BID. Step 3: 5mg TID. Step 4: 10mg QAM, 5mg BID. Step 5: 10mg BID, 5mg QMid-day. Step 6: 10mg TID. Step 6 will last up to 2 weeks. De-escalation will start from highest dose step and work backwards in 2-day intervals. Complete drug administration of escalating, staying constant at 10mg TID and de-escalating will be done with both drug and placebo.
Study: NCT05123781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg Prolonged Release Tablets (JSC Farmak, Ukraine)
Description: One tablet of the test product was administered orally with 240 ml of water
Study: NCT00640003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo drug
Study: NCT03213509

Intervention type: OTHER
Intervention: Interview (Social and Verbal Autopsy)
Description: Verbal autopsy is a technique used to determine the cause of death by asking caregivers, friends or family members about signs and symptoms exhibited by the deceased in the period before death. This is usually done using a standardized questionnaire that collects details on signs, symptoms, complaints and any medical history or events. The cause of death, or the sequence of causes that led to death, are assigned based on the data collected by this questionnaire and on any other available information. The social autopsy tool is used in conjunction with the verbal autopsy tool to explore the non-biological factors contributing to a death, including the social, behavioural and health systems determinants of maternal and child deaths.

Intervention type: OTHER
Intervention: Interview (Social and Verbal Autopsy)
Description: Verbal autopsy is a technique used to determine the cause of death by asking caregivers, friends or family members about signs and symptoms exhibited by the deceased in the period before death. This is usually done using a standardized questionnaire that collects details on signs, symptoms, complaints and any medical history or events. The cause of death, or the sequence of causes that led to death, are assigned based on the data collected by this questionnaire and on any other available information. The social autopsy tool is used in conjunction with the verbal autopsy tool to explore the non-biological factors contributing to a death, including the social, behavioural and health systems determinants of maternal and child deaths.
Study: NCT02461186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arterolane maleate-piperaquine phosphate (Synriam)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine phosphate (Duocotexin)
Study: NCT05123781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage® XR 1000 mg Prolonged Release Tablets (Merck Serono Ltd, UK)
Description: One tablet of the Reference product was administered orally with 240 ml of water
Study: NCT04290624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Dentifrice: Stannous Fluoride
Description: Participants will be instructed to dose the toothbrush provided with a strip of dentifrice (a full brush head) on each brushing occasion containing 0.454% w/w Stannous fluoride for 2 minutes twice daily (morning and evening) for 12 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COREGA Denture Foaming Cleanser
Description: Participant will clean their denture using 2 pumps of the denture cleansing foam and a denture cleaning brush for 90 timed seconds outside of the mouth twice daily (morning and evening) for 12 weeks.
Study: NCT04468906

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biceps Tenodesis
Description: Biceps tenodesis describes the surgical procedure that will be performed to treat LHBT lesions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-locking T Tenotomy
Description: Self-locking T Tenotomy describes the surgical procedure that will be performed to treat LHBT lesions.
Study: NCT02729779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Group
Description: Elderly will be submitted to a specific exercise program of modified Pilates method performed in the mat and apparatus. In the first session, participants will receive basic guidance on the Pilates training and activation of the power house. The session will be divided in: global warming and stretching (5 minutes), Pilates exercises for upper and lower limbs, abdomen and spine (45 minutes), global stretching (5 minutes) and local relaxing massage (5 minutes).The session will consist of a minimum of 5 exercises and a maximum of 15 Pilates exercises. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Group
Description: Elderly will be submitted to an exercise program with global stretching (for lower and upper limbs and column with two repetitions and 30 seconds of maintenance in each segment) for 10 minutes, walking on a treadmill for 20 to 40 minutes, and relaxing massage for 5 minutes. The intensity of the effort during walking on a treadmill will be based on a combination of heart rate (based on the percentage of maximum heart rate: 208 - (0.7 x age)) and rate of perceived effort assessed by the Borg scale. Exercise will be performed respecting the fraction of 50-75% of maximum heart rate and levels between 12 to 13 (moderate intensity) of the Borg scale. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
Study: NCT04290624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouth rinse: Sodium Fluoride
Description: Participants will take 10 ml of the mouth rinse containing 90 ppm sodium fluoride and swished around the mouth for 1 minute twice daily (morning and evening) for 12 weeks.
Study: NCT04079738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib
Study: NCT03130348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00719979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (iCBT + TeleCoach)
Description: TABI will include 12 weeks of Internet-based cognitive behavioral therapy (iCBT) combined with brief telephone and email support from a coach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (iCBT + TeleCoach)
Description: TABI will include 12 weeks of Internet-based cognitive behavioral therapy (iCBT) combined with brief telephone and email support from a coach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (I-CBT)
Description: I-CBT will include access to an interactive Web-based intervention designed to teach and facilitate the use of cognitive behavioral skills. The intervention will last 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual / Wait-list control
Description: TAU will include standard treatment from participants' primary care physicians. Participants will be able to choose between TABI and I-CBT treatment options after a 6-week wait-list period.
Study: NCT00726375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept (Enbrel)
Description: Etanercept will begin within 72 hours of the diagnosis of Grade I acute GVHD and after consent for this study. Subjects receive eight doses of etanercept over four weeks. All doses will be administered by SQ injection. All subsequent doses will be given as subcutaneous injections into the skin. Injections will be given twice weekly with at least one day in between injections. The injections can be given in clinic, in the hospital, or self administered injections.
Study: NCT00935831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863A
Description: 50mg, 150mg
Study: NCT01926015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq™ (V260)
Description: Live, oral, pentavalent vaccine containing 5 human-bovine reassortant rotavirus strains

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq™ (V260)
Description: Live, oral, pentavalent vaccine containing 5 human-bovine reassortant rotavirus strains

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTP-IPV
Description: Diphtheria, tetanus, pertussis, inactivated polio vaccine used as part of the Japanese vaccination schedule
Study: NCT00935831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863A
Description: 50mg, 150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863A
Description: 50mg, 150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo
Study: NCT03359915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPD Self-Management Plan
Description: Patient education in use of a COPD self-management action plan supported by monthly visits from, and access to, a CHW who has been trained in the use of a COPD self-management action plan.
Study: NCT02999984

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)
Description: autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Busulfan is used for non-myeloablative conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-ADA ERT
Description: PEG-ADA ERT is discontinued at Day +30 (-3/+15 days) after successful engraftment
Study: NCT02776553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional consultation
Description: Dietary advice will be provided at the beginning of the study and individually tailored to the participant's usual eating habits plus amino acid supplement including 10 grams of branched-chain amino acids
Study: NCT02447692

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PSV ventilation strategy
Description: An algorithm for adjusting the level of pressure support according to usual clinical parameters; patients not tolerating PSV will be switched to Assist/Control mode according to predefined criteria

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PAV+ ventilation strategy
Description: An algorithm for adjusting the level of support (gain) to maintain a predefined range of respiratory muscle pressure; patients not tolerating PAV+ (Puritan Bennett™ 840 or 980 ventilator) will be switched to Assist/Control mode according to predefined criteria
Study: NCT02776553

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional consultation
Description: Dietary advice will be provided at the beginning of the study and individually tailored to the participant's usual eating habits plus amino acid supplement including 10 grams of branched-chain amino acids

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical training program
Description: Physical activity prescription will target ≥10,000 steps/day, taking into account all activities performed throughout the day, although the increment in activity should be no less than 3000 steps/day above the baseline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral modification therapy
Description: The behavior modification theory will be applied in the form of a structured set of cues and questions between investigator and participant at each visit in order to provide individually tailored counseling to enhance internal motivation and facilitate behavior change toward physical activity and dietary improvement that are adaptable to each participant's usual habits.
Study: NCT00190580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan
Description: valsartan, dosage from 20mg to 180mg, once or twice a day plus conventional antihypertensive drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional antihypertensive drugs
Description: Conventional antihypertensive drugs including calcium channel blockers, diuretics, angiotensin converting enzyme inhibitors and/or beta-blockers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional antihypertensive drugs
Description: Conventional antihypertensive drugs including calcium channel blockers, diuretics, angiotensin converting enzyme inhibitors and/or beta-blockers